Growth factor/peptide receptor imaging for the development of targeted therapy in oncology

Current Pharmaceutical Design

Volumn 14, Issue 31, 2008, Pages 3340-3347

  Van de Wiele, Christophe ^a,b   Boersma, Hendricus ^b   Dierckx, Rudi A ^a,b   De Spiegeleer, Bart ^c   Van Waarde, Aren ^b   Elsinga, Philip H ^b  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c GHENT UNIVERSITY   (Belgium)

Author keywords

PET; Receptor imaging; SPECT; Targeted therapie

Indexed keywords

CARBON 11; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUORINE 18; GROWTH FACTOR; IMMUNOGLOBULIN FRAGMENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; NITROGEN 13; OXYGEN 15; PENTETREOTIDE IN 111; PEPTIDE; RADIOPHARMACEUTICAL AGENT; TEMOZOLOMIDE C 11; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN ANTIBODY I 124; DIAGNOSTIC AGENT; RECEPTOR; SIGNAL PEPTIDE;

BREAST CANCER; CANCER HORMONE THERAPY; COLORECTAL CARCINOMA; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DRUG CLEARANCE; DRUG HALF LIFE; DRUG PENETRATION; DRUG RESPONSE; DRUG SCREENING; DRUG STRUCTURE; HUMAN; ISOTOPE LABELING; LUNG NON SMALL CELL CANCER; MOLECULAR IMAGING; NON INVASIVE PROCEDURE; NONHUMAN; ONCOLOGY; PATIENT SELECTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; RECEPTOR DOWN REGULATION; REVIEW; SIGNAL TRANSDUCTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STRUCTURE ANALYSIS; TARGET CELL; TUMOR CELL; ANIMAL; METABOLISM; NEOPLASM; PROTEIN BINDING; SCINTISCANNING;

ANIMALS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PROTEIN BINDING; RADIOPHARMACEUTICALS; RECEPTORS, PEPTIDE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 59649103262     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208786549434     Document Type: Review

References (73)

1. Friday BB, Adjei AA. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin Cancer Res 2008; 14: 342-6.
2. Goh PP, Sze DD, Roufogalis BD. Molecular and cellular regulators of cancer angiogenesis. Curr Cancer Drug Targets 2007; 7: 743-58.
3. Gerber DE. Targeted therapies: A new generation of cancer treatments. Am Pham Phys 2008; 77: 311-9.
4. Pantaleo MA, Saponara M, Nannini M, Biasco G. Targeted therapies in solid tumors: Results and promises. Minerva Med 2007; 98: 603-23.
5. Dahl O, Borkamo E, Fluge O. Current status of antivascular therapy and targeted treatment in the clinic. J Hyperthermia 2008; 24: 97-110.
6. Gollob J, Wilhlem S, Carter C, Kelley S. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol 2006; 33: 392-406.
7. Nunn A. Molecular imaging and personalized medicine: An uncertain future. Cancer Biother Radiopharm 2007; 22: 722-39.
8. Pazdur R. Drug approval entails evaluation of clinical benefit, not just endpoints. Oncol Times 2003; 25: 14-6.
9. Marwick C. Can disease free-survival be a surrogate of overall survival for drug approvals. J National Cancer Inst 2004; 96: 3 (173) NEWS)
10. Rahmin H, Zaidi H. PET versus SPECT: Strengths, limitations and challenges.Nucl Med Commun 2008; 29: 193-207.
11. Wrase J, Reinold M, Beck A, Heinz A. Multimodal imaging with PET, fMRI and genetic research. Forthsch Neurol Psychiat 2008; 76: 278-85.
12. Khan IU, Beck-Sckinger AG. Targeted tumor diagnosis and therapy with peptide hormones as radiopharmaceuticals. Anticancer Agents Med Chem 2008; 8: 186-99.
13. Cai W, Niu H, Chen X. Multimodality maging of the HER-2neu axis in cancer. Eur J Nucl Med 2008; 35: 186-208.
14. Van de Wiele C, Revets H, Mertens N. Radioimmunoimaging: Advances and prospects. QJ Nucl Med Mol Imaging 2004; 48: 317-25.
15. Eckelman W. The testing of putative receptor binding radiotracers in vivo. In: Diksic M, Reba RC Eds. Radiopharmaceuticals and brain pathology studies with PET and SPECT. CRC Press, Boca Raton, 1982: 42-62.
16. Vera D, Krohn K, Scheibe P, Stadolnil R. Identifiability analysis of an in vivo receptor-binding radiopharmacokinetic system. IEEE Trans Biomed Eng 32: 312-22, 1985
17. Koleba T, Ensom M. Pharmacokinetics of intravenous Immunoglobulin: A systematic review. Pharmacotherapy 2006; 26: 813-27.
18. Thurber G, Zaic S, Wittrup K. Theoretic criteria for antibody penetration into solid tumors and micrometastases. J Nucl Med 2007; 48: 995-9.
19. Ward J, King J. Mathematical modelling of drug transport in tumor multicell spheroids and monolayer cultures. Math Biosci 2003; 181: 177-207.
20. Emfietzoglu D, Kostarelos K, Papakostas A, Yang W, Ballangrud A, Song H, et al. Liposome-mediated radiotherapeutics within avascular tumor spheroids: Comparative dosimetry study for various radionuclides, lipsosome systems and a targeting antibody. J Nucl Med 2005; 46: 89-97.
21. Jain R. Transport of molecules across tumor vasculature. Cancer Metastasis Rev 1987; 6: 559-93.
22. Sevick E, Kain R. Measurement of capillary filtration coefficient in a solid tumor. Cancer Res 1991; 51: 1352-5.
23. Ji R. Lymphatic endothelial cells, tumor lymphangiogenesis and metastasis: New insights into intratumoral and peritumoral lymphatics. Cancer Metastasis Rev 2006; 25: 677-94.
24. Fukumura D, Jain R. Tumor microenvironment abnormalities: Causes, consequences and strategies to normalize. J Cell Biochem 2007; 101: 937-49.
25. Berk D, Yuan F, Leunig M, Kain R. Direct in vivo measurement of targeted binding in a human tumor xenograft. Proc Natl Acad Sci USA 1997; 94: 1785-90.
26. Clauss M, Jain R. Interstitial transport of rabbit and sheep antibodies in normal and neoplastic tissue. Cancer Res 1990; 50: 3487-92.
27. Flessner M, Lofthouse J, Zakaria E. In vivo diffusion of immunoglobulin G in muscle; effects of binding, solute exclusion and lymphatic removal. Am J Physiol 1997; 273: H2783-93.
28. Carmeliet P. Angiogenesis in life and disease. Nature 2005: 438: 932-6.
29. Boerman O, Koppe M, Postema E, Corstens F, Oyen W. Radionuclide therapy of cancer with radiolabelled antibodies. Anticancer Agents Med Chem 2007; 7: 335-43.
30. Dearling J, Pedley R. Technological advances in radioimmunotherapy. 2007: 19: 457-69.
31. Goldenberg D, Sharkey R. Novel radiolabeled antibody conjugates. Oncogene 2007; 26: 3734-44.
32. Williams L, Wu A, Yazaki P, Liu A, Raubitschek A, Shively J, Wong J. Numerical selection of optical imaging agents with application to engineered antibodies. Cancer Biother Radiopharm 2001. 16: 25-35.
33. Orlova A, Feldwish J, Abrahmse L, Tolmachev V. Update: Affibody molecules for molecular imaging and therapy for cancer. Cancer Biother Radiopharm 2007; 22: 573-84.
34. Signore A, Annovazi A, Chianelli M, Corsetti F, Van de Wiele C, Waterhouse R. Peptide radiopharmaceuticals for diagnosis and therapy. Eur J Nucl Med 2001. 10: 1555-6.
35. Van den Bossche B, Van de Wiele C. Receptor imaging in oncology by means of nuclear medicine: Current status. J Clin Oncol 2004; 22: 3593-607
36. Ginj M, Zhang H, Waser B, Cescato R, Wild D, Wang XH, et al. Radiolabelled somatostatin antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc Natl Acad Sci USA 2006; 103: 16436-41.
37. Tolmachev V, Carlsson J, Lundqvist H. A limiting factor for the progress of radionuclide based cancer diagnostics and therapy - availability of suitable radionuclides. Acta Oncol 2004; 43: 264-75.
38. Lammertsma A. Radioligand studies: Imaging and quantitative analysis. Eur Neuropsychopharmacol 2002; 12: 513-6.
39. Lammertsma A. PET/SPECT: Functional imaging beyond flow. Vision Res 2001; 41: 1277-81.
40. Bauer M, Wagner C, Langer O. Microdosing studies in humans: The role of positron emission tomography. Drugs R D 2008; 9: 73-81.
41. Saleem A, Brown, G, Brady F, Aboagye E, Osman S, Luthra S, et al. Metabolic activation of temozolamide measured in vivo using positron emission tomography. Cancer Res 2003; 63: 2409-15.
42. Saleem A, Aboagye E, Matthews J, Price P. Plasma pharmacokinetic evaluation of cytotoxic agents radiolabelled with positron emitting radioisotopes. Cancer Chemother Pharmacol 2008; 61: 865-73.
43. Jayson G, Zweit J, Jackson A, Mulatero C, Julyan P, Ranson M, et al. Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: Implications for trial design of antiangiogenic antibodies. J Natl Cancer Inst 2002; 94: 1484-93.
44. Reilly R, Gariépy J. Factors influencing the sensitivity of tumor imaging with a receptor-binding radiopharmaceutical. J Nucl Med 1998; 39: 1036-43.
45. Maini C, Sciuto R, Tofani A, Ferraioni A, Carapella C, Occhipinti E, et al. Somatostatin receptor imaging in CNS tumors using 111In octreotide. Nucl Med Commun 1995; 16: 756-66.
46. Gallup D, Maguire R, Van Nostrand D Eds. Diagnosis of colorectal and ovarian carcinoma: Application of immunoscitnigraphic technology. Multicenter clinical trial of 111In-CYT-103 in patients with ovarian cancer. New York: Marcel Dekker; 1992.
47. Collier B, Abdel-Nabi H, Doerr R, Harwood S, Olsen J, Kaplan E, et al. Immunoscintigraphy performed with Indium-111 labeled CYT-103 in the management of colorectal cancer: Comparison with CT. Radiology 1992; 185: 179-86.
48. Lakshamanan A, Sharp P, Mallard J. The influence of size and radiopharmaceutical concentration ratio on the detection of abnormalities in clinical radionuclide imaging. Br J Radiol 1978; 51: 986-91.
49. Rockoff S, Goodenough D, McIntire K. Theoretical limitations in the immunodiagnostic imaging of cancer with CT and nuclear scanning. Cancer Res 1980: 40: 3054-8.
50. Krenning E, Kwekkeboom D, Bakker W, Breeman W, Kooij P, van Hagen M, et al. Somatostatin receptor scintigraphy with 111In-DTPA-D-Phe1 and 123I-Tyr3-octreotide: The Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993; 20: 716-31.
51. Jardines L, Berger D. Integration of molecular biology intgo prognostic parameters for breast carcinoma. In: Bland K, Copeland E III Eds. The Breast, Comprehensive management of benign and malignant disease. W.B. Saunders Company, Philadelphia: USA 1998; 435-56.
52. Smith P. Conditional neutrality as a method of controlling tumor growth. Riv Biol 2005; 98: 297-303.
53. Zidan J, Dashkovsky I, Stayerman C, Basher W, Cozacov C, Hadary A. Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease. Br J Cancer 2005; 93: 552-6.
54. Vincent-Salomon A, Pierga J, Couturier J, d'Enghien C, Nos C, Sigal-Zafrani B, et al. Her2 status of bone marrow micrometastasis and their corresponding primary tumors in a pilot study of 27 cases: A possible tool for anti-HER2 therapy managmenet? Br J Cancer 2007; 96: 654-9.
55. Tapia C, Savic S, Wagner U, Schönegg R, Novotny H, Grilli B, et al. HER2 gene status in primary breast cancers and matched distant metastases. Breast Cancer Res 2007; 9(3): R31.
56. Reichelt U, Duesedau P, Tsourlakis M, Quaas A, Link B, Schurr P, et al. Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol 2007; 20: 120-9.
57. Loupakis F, Vasile E, Santini D, Masi G, Falcone A, Graziano F. EGF-receptor targeting with monoclonal antibodies in colorectal carcinomas: Rationale for a pharmacogenomic approach. Pharmacogenomics 2008; 9: 55-69.
58. Italiano A, Saint-Paul M, Caroli-Bosc F, Francois E, Bourgeon A, Benchimol D, et al. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors correlates with EGFR expression in related metastatic sites: Biological and clinical implications. Ann Oncol 2005; 16: 1503-7.
59. Bibeau F, Boissière-Michot F, Sabourin J, Gourgou-Bourgade S, Radal M, Penault-Llorca F, et al. Assessment of epidermal growth factor receptor (EGFR) expression in primary colorectal carcinomas and their related metastases on tissue sections and tissue microarray. Virchows Arch 2006; 449: 281-7.
60. Italiano A, Vandenbos F, Otto J, Mouroux J, Fontaine D, Marcy P, et al. Comparison of the epidermal growth factor receptor gene and protein in primary non-small-cell lung cancer and metastatic sites: implications for treatment with EGFR inhibitors. Ann Oncol 2006; 17: 981-5.
61. Padhani A, Ollivier L. The RECIST criteria: Implications for diagnostic radiologists. Br J Radiol 2001; 74: 983-6.
62. Therasse P, Arbuck S, Eisenhauer E, Wanders J, Kaplan R, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 523-8.
63. Hayward J, Carbone P, Heuson J, Kumoaka S, Sgaloff A, Rubens R. Assessment of response to therapy in advanced breast cancer. Eur J Cancer 1977; 13: 89-94.
64. Fogelman I, Coleman R. The bone scan and breast cancer. In: Nuclear Medicine annual. New York: Raven Press 1988: 1-38.
65. Hicks D, Kulkarni S. HER2+breast cancer: Review of biologic relevance and optimal use of diagnostic tools. Am J Clin Pathol 2008; 129: 263-73.
66. Grandal M, Madshus I. Epidermal growth factor receptor and cancer: control of oncogenic signalling by endocytosis. J Cell Mol Med 2008; [Epub ahead of print].
67. Roepstorff K, Grovdal L, Grandal M, Lerdrup M, van Deurs B. Endocytic downregulation of ErbB receptors: Mechanisms and relevance in cancer. Histochem Cell Biol 2008; 129: 563-78.
68. Wiley H. Trafficking of the ErbB receptors and its influence on signalling. Exp Cell Res 2003; 284: 78-88.
69. Xu Y, Song J, Berelowitz M, Bruno JF. Estrogen regulates somatostatin receptor subtype 2 messenger ribonucleic acid expression in human breast cancer cells. Endocrinology 1996; 137: 5634-40.
70. Van den Bossche B, Van Belle S, De Winter F, Signore A, Van de Wiele C. Early prediction of endocrine therapy effect in advanced breast cancer patients using 99mTC-depreotide scintigraphy. J Nucl Med 2006; 47: 6-13.
71. Hamoudeh M, Kamleh MA, Diab R, Fessi H. Radionuclides delivery systems for nuclear imaging and radiotherapy of cancer. Adv Drug Deliv Rev 2008; 60(12): 1329-46.
72. Kersemans V, Kersemans K, Cornelissen B. Cell penetrating peptides for in vivo molecular imaging applications. Curr Pharm Des 2008; 14(24): 2415-47.
73. Papaetis GS, Karapanagiotou LM, Pandha H, Syrigos KN. Targeted therapy for advanced renal cell cancer: Cytokines and beyond. Curr Pharm Des 2008; 14(22): 2229-51.